How India Exports Magnesium to the World

In the United States, magnesium-based pharmaceuticals are subject to stringent regulatory oversight by the Food and Drug Administration (FDA). The approval of Abbreviated New Drug Applications (ANDAs) is a critical pathway for generic magnesium products to enter the U.S. market. According to the FDA's Orange Book, numerous ANDAs have been approved for various magnesium formulations, indicating a competitive market landscape. Notably, Indian pharmaceutical companies have been active participants in this market, with 669 exporters contributing to the supply chain.

The FDA also monitors imported pharmaceuticals through Import Alerts, which serve to protect consumers from products that may violate U.S. regulations. For instance, Import Alert 66-66, updated in October 2024, addresses active pharmaceutical ingredients (APIs) that appear to be misbranded under section 502(f)(1) of the Federal Food, Drug, and Cosmetic Act. While this alert is not specific to magnesium products, it underscores the importance of compliance with labeling and manufacturing standards for all pharmaceutical imports.

In the European Union (EU) and the United Kingdom (UK), magnesium-based pharmaceuticals are regulated by the European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA), respectively. Marketing authorization is mandatory for these products, ensuring they meet safety, efficacy, and quality standards. The EMA conducts periodic safety update report single assessments (PSUSAs) for active substances, including magnesium compounds. For example, in May 2025, the EMA published a PSUSA for magnesium sulfate combined with sodium sulfate and potassium sulfate, resulting in a variation to the marketing authorization. (ema.europa.eu)

Compliance with Good Manufacturing Practice (GMP) standards is essential for exporting pharmaceuticals to the EU and UK. Manufacturers must adhere to the EU GMP guidelines, which encompass quality management, personnel, premises, equipment, documentation, production, and quality control. Regular inspections and audits are conducted to ensure ongoing compliance.

Magnesium sulfate is included in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its importance in global health. The 22nd edition of the list, published in 2021, recognizes magnesium sulfate for its critical role in treating conditions such as eclampsia and severe pre-eclampsia. Additionally, magnesium compounds are standardized in various pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring consistent quality and efficacy across different markets.

In India, magnesium-based pharmaceuticals are regulated by the Central Drugs Standard Control Organisation (CDSCO). These products are typically classified under Schedule H of the Drugs and Cosmetics Act, indicating that they are prescription-only medicines. The National Pharmaceutical Pricing Authority (NPPA) oversees the pricing of essential medicines; however, as of March 2026, there is no specific ceiling price set for magnesium sulfate injections. For exports, manufacturers must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT), ensuring compliance with national regulations and facilitating international trade.

The patent landscape for magnesium-based pharmaceuticals is relatively mature, with many original patents having expired. This has led to increased generic competition, particularly from Indian manufacturers. The presence of 669 active Indian exporters in this sector highlights the competitive nature of the market and the capacity of Indian pharmaceutical companies to meet global demand.

In May 2025, the EMA published a PSUSA for magnesium sulfate combined with sodium sulfate and potassium sulfate, resulting in a variation to the marketing authorization. (ema.europa.eu)

In January 2026, the FDA issued Import Alert 54-14, targeting dietary supplement products from firms that have not met dietary supplement GMP requirements. While not specific to magnesium products, this alert emphasizes the FDA's focus on manufacturing standards.

In March 2024, the UK's Food Standards Agency (FSA) completed a safety assessment of magnesium L-threonate as a novel food for use in food supplements, indicating ongoing evaluations of new magnesium compounds. (food.gov.uk)

In October 2024, the FDA updated Import Alert 66-66, addressing APIs that appear to be misbranded under section 502(f)(1) of the Federal Food, Drug, and Cosmetic Act, highlighting the importance of compliance with labeling and manufacturing standards.

In May 2025, the EMA published a PSUSA for magnesium sulfate combined with sodium sulfate and potassium sulfate, resulting in a variation to the marketing authorization. (ema.europa.eu)

These developments underscore the dynamic regulatory environment surrounding magnesium-based pharmaceuticals and the necessity for manufacturers to stay informed and compliant with evolving standards.

India's pharmaceutical industry heavily relies on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) imported from China. Approximately 70-80% of India's API and KSM requirements are sourced from China, exposing the supply chain to potential disruptions. This dependency became evident during the COVID-19 pandemic, which highlighted vulnerabilities in the global supply chain.

In response, the Indian government introduced the Production Linked Incentive (PLI) scheme to bolster domestic API and KSM manufacturing. This initiative aims to reduce import dependence by promoting local production through financial incentives and infrastructure development. However, rebuilding domestic capabilities is a complex and time-consuming process, and the industry continues to face challenges in achieving self-sufficiency. (pharmanow.live)

The magnesium export market from India is highly concentrated, with the top five exporters accounting for 76.1% of the total export value. Sun Pharmaceutical Industries Limited alone holds a 51.2% share. Such concentration poses significant risks, as disruptions affecting these key players can have widespread implications for the supply chain.

The PLI scheme, initiated to encourage diversification and reduce reliance on a few major suppliers, has seen varying levels of adoption. While some companies have expanded their production capacities, the overall impact on supplier diversification remains limited. Continued efforts are necessary to mitigate single-source risks effectively. (pharmanow.live)

Recent geopolitical tensions have significantly impacted global shipping routes. The 2026 Strait of Hormuz crisis led to a near-total halt in maritime transit through this critical passage, affecting approximately 20% of the world's daily oil supply and causing substantial disruptions in the transportation of goods, including pharmaceuticals.

Additionally, the ongoing Iran conflict has disrupted global supply chains, particularly by halting oil tanker movements through the Strait of Hormuz. This has affected the distribution of pharmaceuticals from India, leading to logistical shortages and rising prices.

• Diversify Supplier Base: Encourage the development of alternative suppliers within India to reduce dependence on a few major exporters.

• Enhance Domestic API Production: Accelerate the implementation of the PLI scheme to strengthen local manufacturing of APIs and KSMs, thereby reducing reliance on imports.

• Strengthen Supply Chain Resilience: Develop contingency plans and alternative shipping routes to mitigate the impact of geopolitical disruptions on logistics.

• Monitor Regulatory Developments: Stay informed about international regulatory changes that may affect export markets and adapt compliance strategies accordingly.

• Invest in Technology and Infrastructure: Upgrade manufacturing facilities and logistics infrastructure to improve efficiency and reduce vulnerability to external shocks.

RISK_LEVEL: HIGH